(S045) Equivalent Survival With Breast-Conserving Therapy and Mastectomy in Young Women Under the Age of 40 With Early-Stage Breast Cancer: A National Registry-Based Stage-by-Stage Comparison

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Our study suggests that while young age may be a poor prognostic factor for breast cancer, there is no evidence that these patients have better outcomes with mastectomy over BCT, supporting the continued use of BCT.

Jason C. Ye, MD, Weisi Yan, MD, PhD, Paul Christos, DrPH, MS, Dattatreyudu Nori, MD, MBBS, Akkamma Ravi, MD, MBBS; Department of Radiation Oncology, New York Presbyterian Hospital/Weill Cornell Medical College; Department of Radiation Oncology, New York Hospital Queens/Weill Cornell Medical College; Division of Biostatistics & Epidemiology, Department of Public Health, Weill Cornell Medical College

PURPOSE: Studies have shown that young patients with early-stage breast cancer (BC) are increasingly getting mastectomy instead of breast-conserving therapy (BCT) despite the lack of clear survival evidence in this approach. We examined the difference between outcomes in young women (aged < 40 yr) treated with BCT vs mastectomy.

METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried for women aged < 40 years and diagnosed with stage I or II invasive BC treated with surgery from 1998–2003. Breast cancer–specific survival (BCSS) and overall survival (OS) were evaluated by Kaplan-Meier survival analysis, and the log-rank test was used to compare survival between treatment categories of interest. Multivariable Cox regression model analysis was performed to estimate the predictors of BCSS.

RESULTS: Of the 7,665 women identified, 3,249 (42%) received BCT, while 2,627 (34%) patients had mastectomy and no radiation. There were also 994 (14%) patients who had lumpectomy but no radiation, and 795 (10%) were treated with mastectomy plus radiation. On multivariate analysis, higher stage, estrogen receptor–negative status, and mastectomy plus radiation were found to have a higher risk of BC mortality. When separated by stage, with a median follow-up of 111 months (based on living patients), the BCT and mastectomy-only groups showed no statistically significant difference in BCSS or OS. There was also no difference in non-BC mortality in any-stage disease between the two treatment groups. The group aged 35–39 years (66% of total) was associated with better 10-year BCSS (88%) and OS (86.1%) compared with patients aged 20–34 years (34% of total), who had 10-year BCSS and OS rates of 84.1% and 82.3%, respectively (P < .001 for both BCSS and OS). When patients of each age group were further subdivided into stages I, IIA, and IIB, there was no statistically significant difference in BCSS or OS between the BCT and mastectomy groups for any stage for those aged 35–39 years or for stages I and IIA in the 20–34-year-old age group. However, in patients aged 20–34 years with stage IIB disease only, the mastectomy-only group (n = 183) had significantly inferior 10-year BCSS (64% vs 79%; P = .004) and OS (61% vs 77%; P = .002) compared with the BCT group (n = 183).

CONCLUSION: Our study suggests that while young age may be a poor prognostic factor for breast cancer, there is no evidence that these patients have better outcomes with mastectomy over BCT, supporting the continued use of BCT.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Related Content